123627 - Virtual MD Anderson Proton Therapy Training Webinar - Thoracic/Liver 04/29/2021

Since 2006, the MD Anderson Proton Therapy Center in Houston has treated more than 10,000 patients with the most advanced radiation treatment available. Proton therapy has allowed MD Anderson to treat cancer with power and precision while sparing healthy tissue and reducing the risk of side effects during and following treatment. MD Anderson has published more than 570 manuscripts on proton therapy and is currently running numerous clinical trials to define the value of proton therapy. We are the first in North America to treat patients with Intensity-Modulated Proton Therapy (IMPT) and continue to pioneer in the treatment of each disease site using IMPT.

MD Anderson is well positioned to educate and expand the global knowledge in the developing field of proton therapy. As the medical industry, insurance companies and the public become more aware of the benefits of utilizing proton therapy, there remains a gap in the knowledge in this field of treatment as proton therapy expands rapidly both nationally and internationally. Proton therapy is very different from photon therapy and the goal of the MD Anderson Proton Therapy Training Program is to bridge this knowledge gap by teaching the value of proton therapy by disease site. Our Proton Therapy Training Program aims to provide the knowledge and expertise to physicians, physicists, dosimetrists, therapists and administrators who are planning to treat patients with IMPT.

1. Incorporate the skills learned through interactive virtual sessions to better prepare for proton therapy treatments, thus improving patient outcomes
2. Incorporate knowledge on the responsibilities of physicians, physicists, dosimetrists and therapists in the treatment of proton therapy and the importance of their roles to provide optimal patient care.Incorporate knowledge on the responsibilities of dosimetrists, physicists and nurses in the treatment of proton therapy and the importance of their roles to provide optimal patient care
3. Apply the knowledge of treatment planning and clinical operations to perform proton therapy in respective centers/locations
4. Gain a greater appreciation and perspective of the steps and personnel needed to perform quality proton therapy

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Steven J. Frank, MD
Professor
MD Anderson Cancer Center

Activity Co-Director

Grant or research support-Other-Hitachi|Paid consultant-Other-Varian|Paid consultant-Boston Scientific Corporation|Grant or research support-Eli Lilly and Company

Gary B. Gunn, MD
Professor
MD Anderson Cancer Center

Activity Co-Director

Nothing to disclose

Joe Y. Chang, MD
Professor
MD Anderson Cancer Center

Faculty

Grant or research support-Bristol-Myers Squibb|Membership on advisory committees or review panels, board membership, etc.-Other-Legion|Membership on advisory committees or review panels, board membership, etc.-Other-Global Oncology One

Eugene J. Koay, MD
MD Anderson Cancer Center

Faculty

Consulting Fee-RenovoRx-|Grant or research support-Philips Medical Systems, Inc.-|Grant or research support-GE Healthcare Bio-Sciences-|Royalties-Taylor and Francis, LLC-

Yupeng Li, MS, DABR
UT MD Anderson Cancer Center

Faculty

Nothing to disclose

Zhongxing Liao, MD, FASTRO, FAAWR
Dr.
MDACC

Faculty

Nothing to disclose

Steven H. Lin, MD
Professor
MD Anderson Cancer Center

Faculty

Grant or research support-Other-Beyond Spring Pharmaceuticals|Grant or research support-Other-Hitachi Chemical Diagnostics|Paid consultant-Other-XRAD Therapeutics|Membership on advisory committees or review panels, board membership, etc.-AstraZeneca|Membership on advisory committees or review panels, board membership, etc.-Other-STCube Pharmaceuticals

Ethan B. Ludmir, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center

Faculty

Nothing to disclose

Matthew S. Ning, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center

Faculty

Nothing to disclose

Kevin Tran, BS
Medical Dosimetrist
MD Anderson Cancer Center

Faculty

Nothing to disclose

Xiaodong Zhang, PhD, ABR
University of Texas, MD Anderson Cancer Center

Faculty

Nothing to disclose

Mayankkumar Amin, M.Sc., CMD
Clinical Supervisor, Medical Dosimetry Proton THerapy
MD Anderson cancer- Proton Therapy Center

Other Planning Committee Member

Nothing to disclose

Rola Georges, MS, CMD
Education Program Coordinator
MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Kelley Gilpin, BBA
Manager
The University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Susan L. McGovern, MD
Associate Professor
MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Xiaorong R Zhu, PhD
Professor
MD Anderson

Other Planning Committee Member

Membership on advisory committees or review panels, board membership, etc.-Other-Mevion Medical Systems

Thursday, April 29, 2021